Factor XIa Inhibitors: Indication-Specific Anticoagulation, Not Broad DOAC Replacement

This narrative review synthesizes 2023–2026 factor XIa inhibitor trial signals into a framework that helps anticoagulation pharmacists distinguish where hemostasis-sparing agents add value versus where they underperform established direct oral anticoagulants.

abelacimabasundexianmilvexianfactor XIa inhibitorsfactor XI inhibitorsanticoagulationatrial fibrillationstroke preventioncancer-associated thrombosisDOACAZALEA-TIMI 71OCEANIC-AFOCEANIC-STROKEnarrative review Cardiology / Anticoagulation

Background Information

Factor XIa inhibitors could transform thrombosis prevention.

Factor XIa inhibition represents a potential breakthrough in thrombosis prevention with distinct patient population benefits. Positive results in secondary stroke prevention and cancer-associated thrombosis with mixed outcomes in atrial fibrillation trials. Evidence suggests targeted use in secondary stroke prevention and cancer-associated thrombosis, but results vary by indication. FXIa inhibitors show promise, but benefits depend on specific clinical scenarios.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Kidder E, Dhanesha N

Citation: Kidder E, Dhanesha N Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning. Current opinion in hematology. 2026. doi:10.1097/MOH.0000000000000941

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →